As pharmaceutical companies harness the potential of cell & gene therapy technologies through innovative patents, strategic investments, and evolving deal trends, they are paving the way for groundbreaking personalized treatments, precision medicine, and transformative advancements in the pharmaceutical industry on a global scale. GlobalData’s cell & gene therapy market report provides comprehensive analysis of the cell & gene therapy market. Buy the report here.

Smarter leaders trust GlobalData

This article presents a quarterly round-up of the latest trends in the pharmaceutical industry regarding cell & gene therapy. It provides an overview of recent developments in cell & gene therapy-related deals, talent acquisition, and patent filings within the pharmaceutical industry.

Diverse applications of cell & gene therapy in pharmaceutical industry

Pharma companies are leveraging new cell & gene therapy technologies through recent patents to innovate and improve their businesses. For example, Sangamo Therapeutics Inc. has patented methods and compositions for treating genetic diseases, while NBIOSE N.V. has developed techniques for producing galactosylated di- and oligosaccharides. These advancements in enzymatic crosslinking, GABAA receptor modulation, and targeting dysfunctional tumor antigen-specific CD8+ T cells in the tumor microenvironment offer promising avenues for personalized treatments and precision medicine. By acquiring these patents, companies can enhance their capabilities in developing novel therapies for a wide range of genetic conditions, ultimately leading to more effective and targeted treatments for patients in the field of cell & gene therapy.

The industry experienced a 20% decline in the number of cell & gene therapy-related patent applications in Q4 2023 compared with the previous quarter. On an annual basis, the number of cell & gene therapy-related patent applications in the pharmaceutical industry witnessed a drop of 3% compared with Q4 2022.

Strategic deal trends in cell & gene therapy in pharmaceutical industry

Pharmaceutical companies are not only focusing on innovation to enhance their patent portfolios but are also making strategic investments in cell & gene therapy. These investments aim to secure lucrative deals with partners and position themselves at the forefront of industry advancements. Some of the recent deals underscore the importance of cell & gene therapy in the pharmaceutical industry.

In Q4 2023, the number of cell & gene therapy-related deals in the pharmaceutical industry grew by 5% compared with Q4 2022. On a quarterly basis, there was 7% drop in the number of deals in Q4 2023 compared with the previous quarter.

Impact on hiring

In terms of new job posting, in Q4 2023, the pharmaceutical industry experienced a 50% drop compared with the previous quarter. On an annual basis, job postings also declined by 80%. Notably, healthcare practitioners and technical occupations, with a share of 33%, emerged as the top cell & gene therapy-related job roles within the pharmaceutical industry in Q4 2023, with new job postings rising by % quarter-on-quarter. Management occupations came in second with a share of 33% in Q4 2023, with new job postings dropping by 75% over the previous quarter. The other prominent cell & gene therapy roles include production occupations with a 33% share in Q4 2023.

Encoded Therapeutics, and Scientifica are among the top companies leading in cell & gene therapy hiring within the pharmaceutical industry.

Countries driving adoption of cell & gene therapy in pharmaceutical industry

The US is the leading country in cell & gene therapy adoption within the pharmaceutical industry, boasting the highest number of cell & gene therapy-related patents, jobs, and deals. Meanwhile, the UK, Australia, Germany and China also maintain significant positions in cell & gene therapy adoption within the pharmaceutical industry.

In conclusion, the evolving landscape of cell & gene therapy in the pharmaceutical industry, characterized by shifting trends in patents, strategic deals, and hiring patterns, underscores its pivotal role in driving innovation, personalized medicine, and transformative healthcare solutions worldwide.

To further understand GlobalData's analysis on cell & gene therapy in the pharmaceutical industry, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData patent analytics tracks patent filings and grants across companies and themes. Proprietary databases on deals and job analytics are used to respectively monitor global deal activity and uncover insights from daily job postings to identify trends, company activities, and industry dynamics across different sectors globally.